Analyse des contraintes dosimétriques obtenues par trois techniques d’irradiation de tumeurs pulmonaires

Beneyton, V.; Billaud, Geneviève; Niederst, C.; Meyer, P.; Bourhala, Khalil; Schumacher, C.; Karamanoukian, D.; Noël, G.

doi:10.1016/j.canrad.2009.07.039

Cited by 7 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The delineation of target volume and organs at risk was performed on a dosimetric CT scan (General Electric LightSpeed QX/i) with contrast injection and 3.75 mm thin joint images. For 4 patients, triple acquisition with blocked inspiration and expiration and free breathing was realized in order to define tumoral movement during the respiratory cycle [ 8 ]. For 8 patients a dosimetric TEP CT has been fused with the dosimetric CT scan.…”

Section: Methodsmentioning

confidence: 99%

Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients

Truntzer¹,

Antoni

Santelmo

et al. 2014

Radiat Oncol

View full text Add to dashboard Cite

AimsRetrospective, monocentric analysis of localized superior sulcus non-small cell cancer (SS-NSCLC), article management.Materials and methodsBetween 2000 and 2010, 42 patients have been treated for a SS-NSCLC. Median age was 54.7 years (34.5-86.8). Nineteen tumors (45.2%) were stage IIB, 18 were stage IIIA (42.9%) and 5 were stage IIIB (11.9%). Twenty-two patients were treated by pre-operative radiotherapy or chemoradiotherapy, 20 received exclusive radiotherapy or chemoradiotherapy. Preoperative and exclusive median radiotherapy doses were 46 Gy (40–47 Gy) and 51.8 Gy (40–70 Gy), respectively. All patients treated with chemotherapy received at least platinum. Mean follow up was 44.1 months (0–128 months).ResultsLocal, loco-regional and metastatic relapses occurred in 11 (26.2%), 2 (4.8%) and 15 patients (35.7%), respectively. Most common metastatic site was cerebral (7 patients, 46.7%). Median disease-free survival (DFS) was 9.7 months (8.9-10.4). One-, 2- and 5- years DFS rates were 44%, 33% and 26.5%, respectively. No prognostic factor was identified.Median overall survival (OS) was 22.6 months (10.4-34.8). One-, 2- and 5- years OS rates were 61.9%, 44.9% and 30.1%, respectively. Univariate prognostic factors for OS were WHO (p = 0.027) and tumoral response (p = 0.05). In multivariate analysis, independent favorable prognostic factors were WHO 0–1 (p = 0.017; OR = 0.316 [CI95% 0.123-0.81) and complete response to treatment (p = 0.035; OR = 0.312 [IC95% 0.106-0.919]).ConclusionThis study highlighted that a good performans status and complete response to treatment are independent factors of OS, whatever the delivered treatment. Brain was the most common metastatic relapse site.

show abstract

Section: Methodsmentioning

confidence: 99%